Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.

ABSTRACT:

Background

Lipoprotein-associated Phospholipase A2 (Lp-PLA2), can exert proinflammatory as well as proatherogenic properties on the vascular wall. The current study sought to evaluate the influence of high Lp-PLA2 levels on indices of arterial wall properties in patients with stable coronary artery disease (CAD).

Methods

Three hundred seventy-four consecutive patients with stable CAD (mean age 61?±?11?years, 89% males) were enrolled in this single-center cross-sectional study. Flow-mediated dilation (FMD) was used to assess endothelial function and augmentation index (AIx) of the central aortic pressure was used to assess reflected waves. ELISA was used to determine Lp-PLA2 serum levels.

Results

After dividing the participants in 3 equal groups based on the tertiles of circulating Lp-PLA2 values, no significant differences were demonstrated between those in the 3rd tertile with Lp-PLA2 values >?138??g/L, in the 2nd tertile with Lp-PLA2 values between 101 and 138??g/L and in the 1st tertile (Lp-PLA2 values ?138??g/L negatively correlated to FMD [b?=?-?0.45 (95% CI: -?0.79 - -0.11), P?= 0.01] and AIx values [b?=?1.81 (95% CI: 0.57-3.05), P?ConclusionsElevated Lp-PLA2 levels relate to endothelial dysfunction and arterial stiffness in patients with stable CAD independently from classical risk factors for CAD, statin use, antihypertensive treatment, and duration of the disease.

SUBMITTER: Mourouzis K 

PROVIDER: S-EPMC7883455 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature